Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Lisdexamfetamine
Elvanse Adult
Routinely available
SMC (1079/15)
29/03/2023
Indication
Indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.
Therapeutic Area
Central nervous system
Status Description
Routinely available in line with national guidance
Formulation
30mg, 50mg and 70mg hard capsules
Comments
-